Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • CMSgtBob CMSgtBob Mar 7, 2012 7:47 AM Flag

    Small Correction Soon?

    Looking at the chart, the RSI is very high at 83, and the PPS has broken through the upper bollinger bands since the run-up started and volume decreasing, normally a sign that it's overbought.

    I'm waiting for the correction to buy more on the dip.

    GLTA
    Bob

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think so as well, Although these corrections are likley to be insignificant till ASCO.
      Note something you may have seen already...

      1
      February 29, 2012
      Company name: Dainippon Sumitomo Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical Inc.
      (US Biotechnology Company)
      Dainippon Sumitomo Pharma Co., Ltd (DSP) (Headquarters: Osaka, Japan; announced that the company has reached an agreement with Boston
      Biomedical Inc. (BBI) (Headquarters: Norwood, MA, USA; Chairman, CEO and CMO:
      Chiang J. Li) on the acquisition of BBI by DSP today.
      According to the terms of the agreement, DSP will make an upfront payment of US$200
      million to the shareholders of BBI and BBI on closing of the acquisition of its shares, and
      thereafter it will make development milestone payments up to US$540 million related to the
      compounds (BBI608 and BBI503) currently being developed by BBI. Furthermore, after
      the launch, DSP will also make milestone payments up to US$1,890 million, based on the
      achievement of various net sales targets with the last milestone being paid upon net sales
      of greater than US$4 billion in any fiscal year. DSP currently aims to commercialize BBI608
      and BBI503 in 2015 or later.
      1. Purpose of the Acquisition of BBI
      BBI is a biotechnology company focusing on the oncology area and possesses two highly
      promising products in their pipeline called BBI608 and BBI503, which are small molecular
      oral drugs created by BBI with the aim to cause an antitumor effect in cancer stem cells.

    • looks like you'll get your chance today

    • Agreed. I think the slowing volume is telling. Really hope it dips a little more. Would love to load up again, but thinking the lowest we will prolly see now is around 2.50, if that.